EBP

EBP cholestenol delta-isomerase

Basic information

Region (hg38): X:48521799-48528716

Previous symbols: [ "CDPX2" ]

Links

ENSG00000147155NCBI:10682OMIM:300205HGNC:3133Uniprot:Q15125AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • MEND syndrome (Moderate), mode of inheritance: XL
  • chondrodysplasia punctata 2, X-linked dominant (Definitive), mode of inheritance: XL
  • X-linked chondrodysplasia punctata 2 (Supportive), mode of inheritance: XL
  • MEND syndrome (Supportive), mode of inheritance: XL
  • X-linked chondrodysplasia punctata 2 (Strong), mode of inheritance: XL
  • MEND syndrome (Strong), mode of inheritance: XL
  • X-linked chondrodysplasia punctata 2 (Definitive), mode of inheritance: XL
  • MEND syndrome (Definitive), mode of inheritance: XL

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Chondrodysplasia punctata 2, X-linked dominant; Male EBP disorder with neurologic defects (MEND syndrome)XLGeneralGenetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testingBiochemical; Craniofacial; Dermatologic; Musculoskeletal; Neurologic; Ophthalmologic830452; 535904; 10391219; 10391218; 11038443; 12503101; 12509714; 18573709; 21634086; 22121851; 22229330; 23307567; 24700572

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the EBP gene.

  • not_provided (138 variants)
  • Chondrodysplasia_punctata_2_X-linked_dominant (67 variants)
  • MEND_syndrome (24 variants)
  • Inborn_genetic_diseases (15 variants)
  • not_specified (10 variants)
  • EBP-related_disorder (8 variants)
  • Connective_tissue_disorder (4 variants)
  • Cleft_palate (1 variants)
  • CHONDRODYSPLASIA_PUNCTATA_2,_X-LINKED_DOMINANT,_ATYPICAL (1 variants)
  • Intellectual_disability (1 variants)
  • See_cases (1 variants)
  • Developmental_disorder (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the EBP gene is commonly pathogenic or not. These statistics are base on transcript: NM_000006579.3. Only rare variants are included in the table.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

EffectPLPVUSLBBSum
synonymous
1
clinvar
2
clinvar
24
clinvar
5
clinvar
32
missense
6
clinvar
25
clinvar
52
clinvar
17
clinvar
2
clinvar
102
nonsense
21
clinvar
21
start loss
0
frameshift
14
clinvar
1
clinvar
1
clinvar
16
splice donor/acceptor (+/-2bp)
4
clinvar
3
clinvar
7
Total 46 29 55 41 7

Highest pathogenic variant AF is 9.10663e-7

Loading clinvar variants...

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
EBPprotein_codingprotein_codingENST00000495186 47559
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.9360.063300000.00
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense1.495596.30.5710.000007891477
Missense in Polyphen1333.230.39121558
Synonymous0.05984141.50.9880.00000352476
Loss of Function2.7408.750.007.03e-7110

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.000.00
Ashkenazi Jewish0.000.00
East Asian0.000.00
Finnish0.000.00
European (Non-Finnish)0.000.00
Middle Eastern0.000.00
South Asian0.000.00
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: Catalyzes the conversion of Delta(8)-sterols to their corresponding Delta(7)-isomers. {ECO:0000269|PubMed:12760743, ECO:0000269|PubMed:8798407, ECO:0000269|PubMed:9894009}.;
Disease
DISEASE: Chondrodysplasia punctata 2, X-linked dominant (CDPX2) [MIM:302960]: A clinically and genetically heterogeneous disorder characterized by punctiform calcification of the bones. The key clinical features of CDPX2 are chondrodysplasia punctata, linear ichthyosis, cataracts and short stature. CDPX2 is a rare disorder of defective cholesterol biosynthesis, biochemically characterized by an increased amount of 8-dehydrocholesterol and cholest-8(9)- en-3-beta-ol in the plasma and tissues. {ECO:0000269|PubMed:10391218, ECO:0000269|PubMed:10391219, ECO:0000269|PubMed:10942423, ECO:0000269|PubMed:11493318, ECO:0000269|PubMed:18176751, ECO:0000269|PubMed:25814754}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: MEND syndrome (MEND) [MIM:300960]: An X-linked recessive disorder associated with a defect in sterol biosynthesis. Disease manifestations and severity are highly variable. Clinical features include intellectual disability, short stature, scoliosis, digital abnormalities, cataracts, and dermatologic abnormalities. {ECO:0000269|PubMed:12503101, ECO:0000269|PubMed:20949533, ECO:0000269|PubMed:24459067, ECO:0000269|PubMed:24700572}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
Steroid biosynthesis - Homo sapiens (human);Simvastatin Action Pathway;Pravastatin Action Pathway;Atorvastatin Action Pathway;Hyper-IgD syndrome;Cholesteryl ester storage disease;Lysosomal Acid Lipase Deficiency (Wolman Disease);Alendronate Action Pathway;Rosuvastatin Action Pathway;Lovastatin Action Pathway;Mevalonic aciduria;Wolman disease;Risedronate Action Pathway;Cerivastatin Action Pathway;Pamidronate Action Pathway;Fluvastatin Action Pathway;Smith-Lemli-Opitz Syndrome (SLOS);Chondrodysplasia Punctata II, X Linked Dominant (CDPX2);CHILD Syndrome;Desmosterolosis;Hypercholesterolemia;Steroid Biosynthesis;Zoledronate Action Pathway;Ibandronate Action Pathway;Metabolism of lipids;Squalene and cholesterol biosynthesis;Metabolism;cholesterol biosynthesis III (via desmosterol);cholesterol biosynthesis II (via 24,25-dihydrolanosterol);superpathway of cholesterol biosynthesis;Metabolism of steroids;cholesterol biosynthesis I;Cholesterol biosynthesis via desmosterol;Cholesterol biosynthesis via lathosterol;Cholesterol biosynthesis (Consensus)

Recessive Scores

pRec
0.0987

Intolerance Scores

loftool
rvis_EVS
-0.14
rvis_percentile_EVS
42.88

Haploinsufficiency Scores

pHI
0.254
hipred
Y
hipred_score
0.531
ghis
0.479

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.539

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Ebp
Phenotype
embryo phenotype; hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); growth/size/body region phenotype;

Gene ontology

Biological process
skeletal system development;cholesterol biosynthetic process;drug transmembrane transport;cholesterol metabolic process;sterol biosynthetic process;hemopoiesis;cholesterol biosynthetic process via desmosterol;cholesterol biosynthetic process via lathosterol
Cellular component
nuclear envelope;endoplasmic reticulum;endoplasmic reticulum membrane;integral component of plasma membrane;cytoplasmic vesicle
Molecular function
C-8 sterol isomerase activity;steroid delta-isomerase activity;transmembrane signaling receptor activity;protein binding;drug transmembrane transporter activity;cholestenol delta-isomerase activity